Edgar	Filing: Harvard	Apparatus	Regenerative	Technology.	Inc Form 4
- 3					

Harvard Apparatus Regenerative Technology, Inc. Form 4 November 05, 2013

FORM	́ Д							OMB A	PPROVAL		
	UNITED		CURITIES A Washington,			IGE (COMMISSION	OMB Number:	3235-0287		
Check this if no long	er		U ,					Expires:	January 31, 2005		
subject to Section 10 Form 4 or	STATEN 6.		SECUR	NERSHIP OF	Estimated a burden hou response	average Irs per					
obligation may conti	Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,See InstructionSection 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type R	esponses)										
1. Name and Ad McNaughtor	ddress of Reporting 1 Thomas	Sym Har	vard Apparatu	ıs Regene	-	-	5. Relationship of Issuer (Chec	Reporting Pers			
(7)			chnology, Inc.								
REGENERA	(First) (ARD APPARAT ATIVE TECH., 5 HILL ROAD	(Mo CUS 11/	ate of Earliest Tra nth/Day/Year) 01/2013	ansaction			Director 10% Owner XOfficer (give titleOther (specify below) below) Chief Financial Officer				
	(Street)		Amendment, Da d(Month/Day/Year)	-			6. Individual or Jo Applicable Line) _X_ Form filed by 0				
HOLLISTO	N, MA 01746						Form filed by M Person				
(City)	(State)	(Zip)	Table I - Non-D	erivative S	ecurit	ies Acc	uired, Disposed of	, or Beneficial	lly Owned		
1.Title of Security (Instr. 3)	3.	Transaction(A) or Disposed of Code (D)				6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
Common Stock	11/01/2013		Code V J	Amount 16,732 (1)	or (D) A	Price \$ 0	(Instr. 3 and 4) 16,732	D			
Common Stock	11/01/2013		J	4,396 (2)	A	\$0	21,128 <u>(3)</u>	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Harvard Apparatus Regenerative Technology, Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	\$ 2.9	11/01/2013		J	5,544 (2)		<u>(4)</u>	11/14/2018	Common Stock, par value \$0.01 per share	5,544
Stock option (right to buy)	\$ 3.27	11/01/2013		J	11,108 (2)		(5)	05/21/2019	Common Stock, par value \$0.01 per share	11,108
Stock option (right to buy)	\$ 5.79	11/01/2013		J	2,769 (2)		<u>(6)</u>	06/02/2021	Common Stock, par value \$0.01 per share	2,769
Stock option (right to buy)	\$ 3.67	11/01/2013		J	4,383 (2)		<u>(7)</u>	06/01/2022	Common Stock, par value \$0.01 per share	4,383
Stock option (right to buy)	\$ 5.22	11/01/2013		J	2,061 (2)		(8)	05/31/2023	Common Stock, par value \$0.01 per share	2,061

Reporting Owners

Reporting Owner Name / Address	Relationships						
F 8	Director	10% Owner	Officer	Other			
McNaughton Thomas C/O HARVARD APPARATUS REGENERATIVE TECH. 84 OCTOBER HILL ROAD			Chief Financial Officer				

8 E S () HOLLISTON, MA 01746

Signatures

/s/ Thomas McNaughton

11/05/2013

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reflects the shares of the Issuer's common stock issued to the reporting person from Harvard Bioscience, Inc. pursuant to the common stock dividend distributed by Harvard Bioscience on November 1, 2013 to effectuate its spin-off of the Issuer. The Reporting Person was entitled to receive the dividend of the Issuer's common stock from Harvard Bioscience because Reporting Person held 66,929 shares of

(1) Entitled to receive the dividend of the Issuer's common stock from Piarvard Bioscience because Reporting Person herd 00,929 shares of common stock of Harvard Bioscience on the record date for the spin-off, being October 21, 2013. Each holder of record was entitled to receive one share of the Issuer's common stock for every four shares of Harvard Bioscience common stock owned by such holder on such record date.

These options and restricted stock units were acquired by the Reporting Person in connection with the adjustment to the existing options and restricted stock units held by the Reporting Person and issued by Harvard Bioscience, Inc. These issuances by the Issuer to the Reporting Person were required in connection with the spin-off of the Issuer by Harvard Bioscience. The share amounts and exercise

(2) prices of these options and restricted stock units issued by the Issuer were set in a manner to ensure the intrinsic value held by the Reporting Person pertaining to the existing awards issued by Harvard Bioscience was maintained immediately following the spin-off. In addition to these grants by the Issuer, to maintain such intrinsic value, adjustments to the existing equity awards issued by Harvard Bioscience were also made in favor of the Reporting Person.

Includes (a) a deferred stock award of 924 restricted stock units which vest on Jan 1, 2014; (b) a deferred stock award of 691 restricted stock units which vest in equal installments on Jan 1, 2014 and Jan 1, 2015; (c) a deferred stock award of 1,712 restricted stock units

- (3) which vest in equal installments on Jan 1, 2014, Jan 1, 2015, and Jan 1, 2016; (d) a deferred stock award of 1,069 stock units which vest in equal installments on Jan 1, 2014, Jan 1, 2015, Jan 1, 2016, and Jan 1, 2017; and (e) 16,732 shares of common stock held by the Reporting Person.
- (4) The options shares vested in four equal installments on September 16, 2009, 2010, 2011 and 2012.
- (5) The option shares vested in four equal installments on January 1, 2010, 2011, 2012 and 2013
- (6) The unvested shares become exercisable in equal installments on January 1 of each of 2014 and 2015.
- (7) The unvested shares become exercisable in equal installments on January 1 of each of 2014, 2015 and 2016.
- (8) The unvested shares become exercisable in equal installments on January 1 of each of 2014, 2015, 2016 and 2017.

Remarks:

This form has been signed under power of attorney.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.